LONDON (dpa-AFX) - AstraZeneca Plc.'s (AZN.L, AZN) triple-combination inhaler, Breztri Aerosphere, has shown positive results in late-stage clinical trials for patients with uncontrolled asthma. The trials, called KALOS and LOGOS, found that the inhaler significantly improved lung function compared to commonly used dual-combination inhalers. The findings suggest Breztri Aerosphere could offer a more effective treatment option for asthma patients.
There were no new safety or tolerability signals identified for Breztri in KALOS or LOGOS, the company said in a statement.
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide including the US, EU, China and Japan.
For More Such Health News, visit rttnews.com.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
